Send to:

Choose Destination
See comment in PubMed Commons below



Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Aug 16 [updated 2008 Jan 08].


64Cu-DOTA-[Pro1,Tyr4]-Bombesin[1-14] (64Cu-MP2346) is a peptide analog of human gastrin-releasing peptide (GRP) conjugated with 64Cu, and it was developed for positron emission tomography (PET) imaging of tumors with overexpressed GRP receptors (GRP-R) (1). 64Cu is a positron emitter with a 19.3% abundance and a physical half-life (t½) of 12.7 h. The amphibian bombesin (BBN or BN), a peptide of 14 amino acids, is an analog of human GRP, a peptide of 27 amino acids, that binds to GRP-R with high affinity and specificity (2, 3). Both GRP and BN share an amidated C-terminus sequence homology of seven amino acids, -Trp-Ala-Val-Gly-His-Leu-Met-NH2. BN-Like peptides have been shown to induce various biological responses in diverse tissues, including the central nervous system (CNS) and the gastrointestinal (GI) system (4, 5). They also act as potential growth factors for both normal and neoplastic tissues. Specific BN receptors (BN-R) have been identified in CNS and GI tissues and a number of tumor cell lines. The BN-R superfamily includes at least four different subtypes, namely the GRP-R subtype (BB2), the neuromedin B receptor subtype (BB1), the BB3 subtype, and the BB4 subtype (6). Overexpression of GRP-R in various human tumors (e.g., breast, prostate, lung, colon, ovarian, and pancreatic cancers) provides opportunities to image tumors with the use of specific molecular imaging agents designed to target the GRP-R (1, 3, 7-9). There have been varying degrees of success in the current development of GRP-R–targeted radiopharmaceuticals for diagnostic or therapeutic applications (9). Various BN analogs have been labeled with 99mTc and 111In for single-photon emission computed tomography (SPECT) imaging (10, 11). BN Analogs labeled with 68Ga, 18F, 86Y, or 64Cu have been studied for PET imaging (1, 12, 13). Breeman et al. (14, 15) prepared two GRP-R agonists, diethylenetriamine pentaacetic acid (DTPA)-[Pro1,Tyr4]BN[1-14] and 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-[Pro1,Tyr4]BN[1-14] (MP2346), for radiometal labeling by replacing pGlu1 and Leu4 in the native BN with DTPA-Pro or DOTA-Pro and with Tyr, respectively. Both MP2346 and DTPA-[Pro1,Tyr4]BN[1-14] were readily labeled with 111In and appeared to be promising radioligands for SPECT imaging. For PET imaging, Biddlecombe et al. (1) prepared and evaluated 64Cu-MP2346 and 86Y-MP2346. The investigators reported distinct differences in the in vivo pharmacokinetics and tumor uptake of these two radioligands; the authors suggested that this may be the result of their differences in peptide-to-receptor affinity, overall chemical charge, and radiometal-chelate stability.

Free Books & DocumentsFree full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons
    Write to the Help Desk